News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
107last 24h
3127last 7d
512● bullish (7d)
311● bearish (7d)
227publishers
Business Wire3d agoneutral
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026Business Wire17d agoneutral
AbCellera to Present at Upcoming Investor Conferences in November 2026MT Newswires27d agoneutral
AbCellera Biologics' ABCL635 Seen With Best-in-Class Potential in Menopause, UBS SaysSimply Wall St.30d agoneutral
AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws FocusMT Newswires30d agoneutral
AbCellera to Present Phase 1/2 ABCL635 Data at Menopause Society MeetingBusiness Wire31d agoneutral
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingBusiness Wire38d agoneutral
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026Simply Wall St.88d agoneutral
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz DealSimply Wall St.89d agoneutral
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 ResultsSimply Wall St.89d agoneutral
AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 DataInsider Monkey90d agoneutral
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth OutlookBarrons.com90d agoneutral
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.Stocktwits90d agoneutral
ABCL Stock Has Rallied 100% This Year - Now All Eyes Are On AbCellera’s Menopause Drug DataGuruFocus.com94d agoneutral
AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...Simply Wall St.102d agoneutral
Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?Insider Monkey130d agoneutral
Is AbCellera Biologics (ABCL) One of the Best Stocks with Biggest Upside?